A Phase 1b/2a Study to Evaluate the Safety of CMTX-101 in Combination with Inhaled Antibiotics in People with Cystic Fibrosis Chronically Infected with Pseudomonas Aeruginosa
Latest Information Update: 20 Jun 2025
At a glance
- Drugs CMTX 101 (Primary)
- Indications Pseudomonal infections
- Focus Adverse reactions
- Sponsors Clarametyx Biosciences
Most Recent Events
- 16 Jun 2025 According to Clarametyx Biosciences media release, the full study enrollment is expected by end of 2025.
- 16 Jun 2025 Interim Results(n=21) presented in the Clarametyx Biosciences media release.
- 28 Jan 2025 According to Clarametyx Biosciences media release, has received investment from the Kineticos AMR Accelerator Fund, extending its Series A funding round from 2024. This investment will support the company's pipeline, including the ongoing CMTX-101 trial.